MARKET

AUTL

AUTL

AUTOLUS THERAPEUTICS PLC
NASDAQ
1.320
+0.020
+1.59%
Pre Market: 1.310 -0.01 -0.76% 06:10 11/11 EST
OPEN
1.210
PREV CLOSE
1.320
HIGH
1.380
LOW
1.120
VOLUME
294
TURNOVER
0
52 WEEK HIGH
2.580
52 WEEK LOW
1.120
MARKET CAP
351.33M
P/E (TTM)
-1.3717
1D
5D
1M
3M
1Y
5Y
1D
Autolus presents longer-term CARLYSLE lupus data at rheumatology meeting
TipRanks · 16h ago
Autolus Therapeutics Presents Longer-Term Follow Up Data From Ongoing CARLYSLE Phase 1 Trial; Data Show Clinically Significant Improvements In SLEDAI-2K Scores And Achievement Of DORIS In Most Patients Despite Severe Disease Activity At Baseline
Benzinga · 16h ago
Autolus Therapeutics reports Q3 EPS (21c), consensus (17c)
TipRanks · 21h ago
Autolus Therapeutics backs FY26 revenue view $150M, consensus $149.78M
TipRanks · 21h ago
Autolus Therapeutics Q3 2026 Earnings Call Transcript
Benzinga · 23h ago
Autolus Reports Strong Third-Quarter AUCATZYL Revenue Growth
TipRanks · 1d ago
Autolus Therapeutics GAAP EPS of -$0.21 misses by $0.03, revenue of $41.24M beats by $1.21M
Seeking Alpha · 1d ago
Autolus Therapeutics FY2026 AUCATZYL net product revenue expected to be more than $150.000M
Benzinga · 1d ago
More
About AUTL
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.

Webull offers Autolus Therapeutics PLC (ADR) stock information, including NASDAQ: AUTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUTL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AUTL stock methods without spending real money on the virtual paper trading platform.